Abstract 1661: Humanized Mouse Models for Immune-Oncology Biotherapeutics: Development, Validation and Applications
Gang Chen,Bin Cai,Feng Zhou,Jerry Zhou,Jie Liu,Xin Dong
DOI: https://doi.org/10.1158/1538-7445.am2017-1661
IF: 11.2
2017-01-01
Cancer Research
Abstract:Abstract With clinical success and FDA approval of Ipilimumab, Nivolumab, Pembrolizumab and Atezolizumab, developing biotherapeutics against immune checkpoint targets, like CTLA-4, PD-1/PDL-1 and others, becomes hot pursuits for big pharma and biotech. However, traditional syngeneic models with surrogate murine reagents or human immune cell re-constitution in immune deficient mice are useful but not reliable and robust due to the species specificity and highly variable responses. It is crucial to establish additional preclinical models for efficacy assessment of investigational immune-oncology antibodies before entering clinic. Establishing human therapeutic target engineered mouse models by replacing mouse gene with human counterpart while maintaining intact mouse immunity is a practical approach for in vivo studies. Applying CRISPR-Cas9 and other gene editing techniques, we have engineered genetically a series of single and double human immune-checkpoint genes, like PD-1/PDL-1, CTLA-4, TIM3, CD137 and others, knock-in model expressing chimeric human/mouse targets composed of human extracellular domains, with intact mouse signal peptide and intracellular domain. FACS analysis of immune cells derived from homozygous knock-in mice showed that activated cells only express chimeric targets reactive to anti human target antibodies, but not mouse gene specific antibodies. We have been testing the efficacy of reference antibodies by treating these homozygous knock-in mice inoculated with syngeneic murine tumor cells. Other applications, like target validation, combination therapy and biomarker discovery, are also explored. Note: This abstract was not presented at the meeting. Citation Format: Gang Chen, Bin Cai, Feng Zhou, Jerry Zhou, Jie Liu, Xin Dong. Humanized mouse models for immune-oncology biotherapeutics: Development, validation and applications [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1661. doi:10.1158/1538-7445.AM2017-1661